GYREGyre Therapeutics, Inc.
$6.76-7.0% 1Y
$6.76
$5.5652 weeks$8.87
The financials
Gyre Therapeutics, Inc. by the numbers
Gyre Therapeutics, Inc. (GYRE) reported revenue of $29M in Q2 2026 (quarter ended Jun 30, 2026), down 2.1% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $14M. For the full year FY2025, revenue was $117M (+10% year on year) and net income $9.9M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $29M | $30M | −2.1% |
| Gross profit | $27M | $26M | +5.0% |
| Operating income | −$14M | −$2.2M | n/a |
| Net income | −$14M | −$2.2M | n/a |
| Diluted EPS | −$0.12 | −$0.03 | n/a |